745 related articles for article (PubMed ID: 35051990)
21. Omicron BA.1-specific T-cell responses in adults vaccinated with CoronaVac or BNT162b2 in Hong Kong: an observational cohort study.
Mok CKP; Chen C; Zhao S; Sun Y; Yiu K; Chan TO; Lai HL; Lai KC; Lau KM; Ling KC; Chan KKP; Ng SS; Ko FW; Peiris M; Hui DS
Lancet Microbe; 2023 Jun; 4(6):e418-e430. PubMed ID: 37086735
[TBL] [Abstract][Full Text] [Related]
22. Boosting with Multiple Doses of mRNA Vaccine after Priming with Two Doses of Protein Subunit Vaccine MVC-COV1901 Elicited Robust Humoral and Cellular Immune Responses against Emerging SARS-CoV-2 Variants.
Chiu CH; Chang YH; Tao CW; Chang FY; Chiu KC; Chang TW; Yen LC
Microbiol Spectr; 2022 Oct; 10(5):e0060922. PubMed ID: 36005765
[TBL] [Abstract][Full Text] [Related]
23. Immunogenicity, durability, and safety of an mRNA and three platform-based COVID-19 vaccines as a third dose following two doses of CoronaVac in China: A randomised, double-blinded, placebo-controlled, phase 2 trial.
Zhang Y; Ma X; Yan G; Wu Y; Chen Y; Zhou Z; Wan N; Su W; Liu FW; Dai MX; Yang M; Li C; Yu X; Zhang L; Wang Z; Zhou TC; You D; Wei J; Zhang Z;
EClinicalMedicine; 2022 Dec; 54():101680. PubMed ID: 36188435
[TBL] [Abstract][Full Text] [Related]
24. Real-world effectiveness of homologous and heterologous BNT162b2, CoronaVac, and AZD1222 booster vaccination against Delta and Omicron SARS-CoV-2 infection.
Suah JL; Tng BH; Tok PSK; Husin M; Thevananthan T; Peariasamy KM; Sivasampu S
Emerg Microbes Infect; 2022 Dec; 11(1):1343-1345. PubMed ID: 35499301
[TBL] [Abstract][Full Text] [Related]
25. Immunological responses and adverse reactions of the heterologous second booster dose of BNT162b2 after two-dose CoronaVac for COVID-19 vaccination in healthcare workers of Faculty of Medicine, Naresuan University.
Makanut S; Wangteeraprasert A; Jitpewngam W; Ngoenkam J; Pongcharoen S
Vaccine; 2023 Jun; 41(29):4335-4340. PubMed ID: 37301707
[TBL] [Abstract][Full Text] [Related]
26. Vaccine-Induced Antibody Responses against SARS-CoV-2 Variants-Of-Concern Six Months after the BNT162b2 COVID-19 mRNA Vaccination.
Jalkanen P; Kolehmainen P; Haveri A; Huttunen M; Laine L; Österlund P; Tähtinen PA; Ivaska L; Maljanen S; Reinholm A; Belik M; Smura T; Häkkinen HK; Ortamo E; Kantele A; Julkunen I; Lempainen J; Kakkola L
Microbiol Spectr; 2022 Apr; 10(2):e0225221. PubMed ID: 35262410
[TBL] [Abstract][Full Text] [Related]
27. Induction of SARS-CoV-2 neutralizing antibodies by CoronaVac and BNT162b2 vaccines in naïve and previously infected individuals.
Muena NA; García-Salum T; Pardo-Roa C; Avendaño MJ; Serrano EF; Levican J; Almonacid LI; Valenzuela G; Poblete E; Strohmeier S; Salinas E; Muñoz A; Haslwanter D; Dieterle ME; Jangra RK; Chandran K; González C; Riquelme A; Krammer F; Tischler ND; Medina RA
EBioMedicine; 2022 Apr; 78():103972. PubMed ID: 35366624
[TBL] [Abstract][Full Text] [Related]
28. BNT162b2 booster after heterologous prime-boost vaccination induces potent neutralizing antibodies and T cell reactivity against SARS-CoV-2 Omicron BA.1 in young adults.
Seidel A; Zanoni M; Groß R; Krnavek D; Erdemci-Evin S; von Maltitz P; Albers DPJ; Conzelmann C; Liu S; Weil T; Mayer B; Hoffmann M; Pöhlmann S; Beil A; Kroschel J; Kirchhoff F; Münch J; Müller JA
Front Immunol; 2022; 13():882918. PubMed ID: 35958601
[TBL] [Abstract][Full Text] [Related]
29. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
Front Immunol; 2022; 13():863554. PubMed ID: 35711445
[TBL] [Abstract][Full Text] [Related]
30. Humoral immune response in people living with HIV after administration of SARS-CoV-2 vaccine CoronaVac or BNT162b2 or CoronaVac/BNT162b2 booster sequence: A cross-sectional study.
Wolff M; Charpentier P; Canals A; Vial C; Hormazábal J; Cortés J; Silva M
Vaccine; 2024 Jan; 42(3):671-676. PubMed ID: 38123398
[TBL] [Abstract][Full Text] [Related]
31. Immunogenicity of bivalent omicron (BA.1) booster vaccination after different priming regimens in health-care workers in the Netherlands (SWITCH ON): results from the direct boost group of an open-label, multicentre, randomised controlled trial.
Tan NH; Geers D; Sablerolles RSG; Rietdijk WJR; Goorhuis A; Postma DF; Visser LG; Bogers S; van Dijk LLA; Gommers L; van Leeuwen LPM; Boerma A; Nijhof SH; van Dort KA; Koopmans MPG; Dalm VASH; Lafeber M; Kootstra NA; Huckriede ALW; van Baarle D; Zaeck LM; GeurtsvanKessel CH; de Vries RD; van der Kuy PHM;
Lancet Infect Dis; 2023 Aug; 23(8):901-913. PubMed ID: 37088096
[TBL] [Abstract][Full Text] [Related]
32. Heterologous Prime-boost of SARS-CoV-2 inactivated vaccine and mRNA BNT162b2 among Healthy Thai Adolescents.
Puthanakit T; Nantanee R; Jaru-Ampornpan P; Chantasrisawad N; Sophonphan J; Meepuksom T; Jupimai T; Sodsai P; Anugulruengkitt S; Hirankarn N;
Vaccine X; 2022 Dec; 12():100211. PubMed ID: 36059600
[TBL] [Abstract][Full Text] [Related]
33. Persistence of immunity against Omicron BA.1 and BA.2 variants following homologous and heterologous COVID-19 booster vaccines in healthy adults after a two-dose AZD1222 vaccination.
Assawakosri S; Kanokudom S; Chansaenroj J; Suntronwong N; Auphimai C; Nilyanimit P; Vichaiwattana P; Thongmee T; Duangchinda T; Chantima W; Pakchotanon P; Srimuan D; Thatsanatorn T; Klinfueng S; Sudhinaraset N; Mongkolsapaya J; Wanlapakorn N; Honsawek S; Poovorawan Y
Int J Infect Dis; 2022 Sep; 122():793-801. PubMed ID: 35863731
[TBL] [Abstract][Full Text] [Related]
34. Immunogenicity of a fractional or full third dose of AZD1222 vaccine or BNT162b2 messenger RNA vaccine after two doses of CoronaVac vaccines against the Delta and Omicron variants.
Niyomnaitham S; Jongkaewwattana A; Meesing A; Pinpathomrat N; Nanthapisal S; Hirankarn N; Siwamogsatham S; Kirdlarp S; Chaiwarith R; Lawpoolsri S; Phanthanawiboon S; Thitithanyanont A; Hansasuta P; Chaiyaroj S; Pitisuttithum P
Int J Infect Dis; 2023 Apr; 129():19-31. PubMed ID: 36682680
[TBL] [Abstract][Full Text] [Related]
35. Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost.
Ai J; Zhang H; Zhang Y; Lin K; Zhang Y; Wu J; Wan Y; Huang Y; Song J; Fu Z; Wang H; Guo J; Jiang N; Fan M; Zhou Y; Zhao Y; Zhang Q; Liu Q; Lv J; Li P; Qiu C; Zhang W
Emerg Microbes Infect; 2022 Dec; 11(1):337-343. PubMed ID: 34935594
[No Abstract] [Full Text] [Related]
36. Booster BNT162b2 COVID-19 Vaccination Increases Neutralizing Antibody Titers Against the SARS-CoV-2 Omicron Variant in Both Young and Elderly Adults.
Um J; Choi YY; Kim G; Kim MK; Lee KS; Sung HK; Kim BC; Lee YK; Jang HC; Bang JH; Chung KH; Oh MD; Park JS; Jeon J
J Korean Med Sci; 2022 Mar; 37(9):e70. PubMed ID: 35257525
[TBL] [Abstract][Full Text] [Related]
37. SARS-CoV-2 specific antibody responses in healthcare workers after a third booster dose of CoronaVac or BNT162b2 vaccine.
Yavuz E; Günal Ö; Başbulut E; Şen A
J Med Virol; 2022 Aug; 94(8):3768-3775. PubMed ID: 35434796
[TBL] [Abstract][Full Text] [Related]
38. Plaque-neutralizing antibody to BA.2.12.1, BA.4 and BA.5 in individuals with three doses of BioNTech or CoronaVac vaccines, natural infection and breakthrough infection.
Cheng SS; Mok CK; Li JK; Ng SS; Lam BH; Jeevan T; Kandeil A; Pekosz A; Chan KC; Tsang LC; Ko FW; Chen C; Yiu K; Luk LL; Chan KK; Webby RJ; Poon LL; Hui DS; Peiris M
J Clin Virol; 2022 Nov; 156():105273. PubMed ID: 36081282
[TBL] [Abstract][Full Text] [Related]
39. Effects of Omicron Infection and Changes in Serum Antibody Response to Wild-Type, Delta, and Omicron After a Booster Dose With BNT163b2 Vaccine in Korean Healthcare Workers.
Lim SH; Kim HJ; Kim SH; Choi SH; Kim B; Kim JY; Ji YS; Kim T; Choo EJ; Jung JC; Moon JE; Kim CK; Park SK; Yun J
J Korean Med Sci; 2023 Apr; 38(13):e103. PubMed ID: 37012688
[TBL] [Abstract][Full Text] [Related]
40. Age-dependent impairment in antibody responses elicited by a homologous CoronaVac booster dose.
Filardi BA; Monteiro VS; Schwartzmann PV; do Prado Martins V; Zucca LER; Baiocchi GC; Malik AA; Silva J; Hahn AM; Chen NFG; Pham K; Pérez-Then E; Miric M; Brache V; Cochon L; Larocca RA; Mendez RDR; Bardini Silveira D; Pinto AR; Croda J; Yildirim I; Omer SB; Ko AI; Vermund SH; Grubaugh ND; Iwasaki A; Lucas C; ; Vogels CBF; Breban M; Koch TR; Chaguza C; Tikhonova I; Castaldi C; Mane S; De Kumar B; Ferguson D; Kerantzas N; Peaper D; Landry ML; Schulz W
Sci Transl Med; 2023 Feb; 15(683):eade6023. PubMed ID: 36791210
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
